Compare Eaton Corporation plc (ETN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Mesoblast Limited — how do they compare? Eaton Corporation plc trades at $425.45 (market cap $164.88B), while Mesoblast Limited trades at $14.13 (market cap $1.75B). The key difference: Eaton Corporation plc is far larger — about 94.2× Mesoblast Limited's market cap, and Eaton Corporation plc pays a 1.04% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Mesoblast Limited for 14 Days on average.
| ETN | MESO | |
|---|---|---|
Market Cap | $164.88B | $1.75B |
Volume | 2,535,086 | 239,027 |
Sector | Industrials | Health |
52-Week High | $459.96 | $20.96 |
52-Week Low | $315.82 | $13.19 |
Typical Hold Time | 31 Days | 14 Days |
Enterprise Value | $185.51B | $1.83B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $424.64, down 1.55% today, with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. ETN maintains robust profitability with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Recent news highlights growing investor attention and positive analyst coverage.
ETN presents a compelling growth story driven by data center demand and grid modernization, with 70% analyst buy ratings and a $502.38 consensus price target suggesting 18% upside. However, elevated valuation multiples (P/E 43.23) and bearish technical indicators warrant caution. Key risks include execution of acquisition strategy and competitive pressures in the electronics manufacturing sector.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
